Objectives: To compare the antimicrobial susceptibility of Prevotella spp. isolated from cystic fibrosis (CF) and non-CF patients and analyse the impact of antibiotic prescribing in the preceding year on resistance amongst CF isolates.
Introduction
Prevotella spp. are obligate anaerobic bacteria and common members of the healthy microbiota at various body sites, including the oral cavity and the respiratory tract. 1, 2 Recently, Prevotella spp. have been detected as part of diverse polymicrobial communities in respiratory samples from cystic fibrosis (CF) patients. 3 -8 Although their precise role in CF lung disease is not yet clear, they may be clinically significant pathogens and contribute to infection and inflammation in the CF lung.
Antibiotics are employed extensively to treat CF pulmonary infection and several studies have examined the effect of persistent antibiotic use on bacterial resistance. For example, long-term macrolide exposure has been shown to significantly increase macrolide resistance amongst both respiratory pathogens and members of the oral flora in patients with CF, non-CF bronchiectasis and chronic obstructive pulmonary disease (COPD). 9 Exposure of other members of the CF microbiota, such as Prevotella spp., to antibiotics used in the treatment of CF pulmonary infection may also increase their resistance to antimicrobials. Therefore, in this study, we determined the antimicrobial susceptibility of a large number of clinical Prevotella isolates cultured from patients with CF and those without CF and analysed the impact of antibiotic prescribing on resistance amongst CF isolates. Of the 12 antibiotics selected, 9 (amoxicillin, co-amoxiclav, azithromycin, ceftazidime, chloramphenicol, clindamycin, doxycycline, meropenem and piperacillin/tazobactam) are used in the treatment of CF lung infection and have putative activity against anaerobes. One antibiotic (tobramycin) is used to treat CF lung infection, but has no putative anaerobic activity, and two antibiotics 
Methods

Bacterial isolates and prior antibiotic use
The clinical Prevotella isolates (n¼157) used in this study were split into four groups: (i) 57 isolates cultured from 25 adult (≥18 years) UK CF patients attending the CF clinic, Belfast, UK [cultured from sputum (n ¼53) and plaque (n ¼4)]; (ii) 23 isolates cultured from 15 paediatric (,18 years) US CF patients attending the CF clinic, University of North Carolina, Chapel Hill, NC, USA [cultured from bronchoalveolar lavage fluid (n¼14) and sputum (n¼9)]; (iii) 50 isolates from invasive infections, including cultures from blood, abscesses and ulcers, from 50 UK non-CF patients, kindly provided by Dr Valerie Hall (Anaerobe Reference Laboratory, Cardiff, UK); and (iv) 27 isolates from 15 adult (≥18 years) UK healthy control subjects (cultured from induced sputum). Information on intravenous and oral antibiotics prescribed in the year preceding culture of UK and US CF isolates was collected from patient hospital notes where available (Tables S1 and S2 , available as Supplementary data at JAC Online). Quality assurance testing was performed using Bacteroides fragilis ATCC 25285, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 29213 and Streptococcus pneumoniae ATCC 49619.
Antimicrobial susceptibility testing and b-lactamase production
The antimicrobial susceptibility of isolates was determined by Etest (AB Biodisk, Hampshire, UK) in accordance with the manufacturer's instructions. MICs were categorized as indicating resistance, intermediate resistance or susceptibility according to the MIC breakpoints for anaerobes defined by the CLSI (Table 1) . b-Lactamase production was determined using a nitrocefin assay as described previously. 10 
Data analysis
The susceptibility (MIC) of UK isolates in the three groups (CF, invasive and healthy control) to each antibiotic was compared using the KruskalWallis test, with post hoc tests performed using the Mann-Whitney test with Bonferroni adjustment applied. The UK and US CF isolates were grouped according to patient prescription of azithromycin (current prescription versus no current prescription) and azithromycin MICs compared using the Mann-Whitney test. Spearman's rank correlation coefficient was used to measure the strength of the linear association between azithromycin MICs and clindamycin resistance. The CF isolates were also grouped according to patient prescription of b-lactam and tetracycline antibiotics in the year prior to pulmonary sample collection (prescription versus no prescription in the previous year) and b-lactam and tetracycline antibiotic MICs compared using the Mann-Whitney test. MICs were also compared in b-lactamase-positive versus b-lactamase-negative isolates using the Mann-Whitney test.
Results
Antimicrobial susceptibility of isolates from a range of sources
The MIC results are summarized in Table 1 . Clindamycin (56%), tetracycline (49%) and co-amoxiclav (21%) resistance was highest in the UK CF Prevotella isolates, with reduced susceptibility to amoxicillin and ceftazidime also apparent in each group. All isolates had high MICs of tobramycin (≥64 mg/L). Resistance to azithromycin was evident among the UK CF, UK invasive and US CF isolates (MIC 90 .256 mg/L), but was less apparent in the UK healthy control isolates (MIC 90 3 mg/L). All isolates tested were susceptible to meropenem, piperacillin/tazobactam and chloramphenicol, with resistance to metronidazole (3%) rare.
Comparison of antimicrobial susceptibility between UK CF, invasive and healthy control isolates
Comparison of the MICs for UK isolates (Table 1 ) showed significant differences for ceftazidime (P¼ 0.035), clindamycin (P,0.001), co-amoxiclav (P,0.001), meropenem (P ¼ 0.001), azithromycin (P,0.001), chloramphenicol (P ¼ 0.014) and doxycycline (P ¼ 0.020), with no differences evident for the remaining five antibiotics. Post hoc tests revealed that CF isolates had significantly higher MICs of clindamycin (P,0.001) and azithromycin (P,0.001) compared with invasive and healthy control isolates. Although there was no difference in either co-amoxiclav or doxycycline MICs between the CF and invasive isolates, both these groups had significantly higher MICs of co-amoxiclav (CF, P,0.001; invasive, P ¼ 0.012) and doxycycline (CF, P¼ 0.027; invasive, P ¼0.03) compared with healthy control isolates.
For antibiotics with breakpoints approved by the CLSI, we determined the risk of antimicrobial non-susceptibility in UK CF isolates relative to invasive isolates (Table 2 ). Significant differences in clindamycin (P,0.001) and co-amoxiclav (P ¼ 0.037) resistance were observed. The likelihood of non-susceptibility to clindamycin and co-amoxiclav in CF isolates was 5.5-fold and 2.5-fold higher relative to that in invasive isolates, respectively.
Current azithromycin prescription and antibiotic resistance in CF isolates
To investigate whether increased resistance to azithromycin was associated with current prescription of the antibiotic, isolates were grouped [current prescription isolates (n¼30) versus no current prescription isolates (n¼ 32)], with current prescription clearly associated with significantly higher azithromycin MICs (P ¼ 0.005; Figure 1 ). Furthermore, isolates from CF patients not currently prescribed azithromycin (n¼ 32) had significantly higher azithromycin MICs (P ¼0.011) compared with isolates (n¼ 17) from UK healthy controls who were also not currently prescribed azithromycin (Figure 1 ). There was also a positive correlation between clindamycin resistance and high azithromycin MICs (r¼ 0.785, P,0.001).
b-Lactam/tetracycline prescription in the year preceding sample collection and antibiotic resistance Prescription of a b-lactam antibiotic (Tables S1 and S2) [prescription (n¼ 43) versus no prescription (n¼ 27)] was associated with a significantly higher MIC of amoxicillin (P ¼ 0.011), but not other b-lactam antibiotics. Similarly, significant associations were apparent between prescription of a cephalosporin [prescription (n¼ 11) versus no prescription (n¼58)] and higher MIC of ceftazidime (P ¼ 0.009) and prescription of a tetracycline and higher MICs of tetracycline (P ¼0.007) and doxycycline (P ¼ 0.043). 
Discussion
Prevotella spp. have been detected by culture in 30% of respiratory samples from CF patients, 4 with molecular studies reporting detection in a higher percentage of samples. 7, 8 Similarly, Prevotella spp. are frequently detected as part of the normal airway microbiota of healthy individuals. 2, 3 As Prevotella may potentially contribute to infection and inflammation in the CF lung, we determined the susceptibility of clinical Prevotella isolates to a range of antibiotics. Meropenem, piperacillin/tazobactam and chloramphenicol all demonstrated excellent in vitro activity, with all isolates tested being susceptible. Previous studies have also reported all Prevotella isolates as susceptible to piperacillin/ tazobactam, 11, 12 whilst meropenem resistance is rare 11 and chloramphenicol resistance amongst Prevotella has yet to be detected. 13 Furthermore, metronidazole resistance was only detected in a small number of isolates. Co-amoxiclav resistance (21%) was highest in the UK CF isolate group and exceeded the levels reported by others. 11, 14, 15 When the three UK groups were compared, CF isolates demonstrated significantly higher MICs of both azithromycin and clindamycin than observed for invasive and healthy control isolates. These resistance levels exceed those reported previously for clinical isolates from a range of body sites. 11, 14, 15 Increased macrolide resistance amongst CF Prevotella isolates is similar to that previously reported for the CF-associated Streptococcus milleri group by Sherrard et al.
Grinwis et al., 16 who linked increased macrolide resistance with chronic exposure to azithromycin. We also found that current prescription of azithromycin was associated with significantly higher azithromycin MICs, corroborating the results of recent clinical trials in CF, non-CF bronchiectasis and COPD, 9, 17, 18 which reported an association between chronic macrolide exposure and increased resistance amongst respiratory pathogens and members of the airway microbiota. As serum azithromycin levels could not be measured in CF patients, we cannot conclude with absolute certainty the true exposure of Prevotella isolates to this antibiotic. Nevertheless, our results indicate that azithromycin exposure may lead to increased resistance amongst organisms such as Prevotella resident in the CF airway microbiota.
We also found that higher MICs of b-lactam/tetracycline antibiotics were associated with their prescription in the previous year, suggesting that resistance to these antibiotics amongst Prevotella in the CF airway microbiota is not intrinsic, but selected by previous antibiotic treatment. Furthermore, 59% of isolates were positive for production of b-lactamases, which may shield them and other bacteria from the effect of b-lactam antibiotics; 19 higher concentrations of amoxicillin, ceftazidime, co-amoxiclav and meropenem were required to inhibit growth of b-lactamase-positive compared with b-lactamase-negative isolates. Therefore, to optimize the treatment of CF pulmonary infection, whilst minimizing the development of resistance, physicians may need to consider the synergistic interactions that are occurring between bacteria within the polymicrobial lung microbiota.
In conclusion, this study has shown that Prevotella isolated from CF airways are significantly more resistant to azithromycin, clindamycin and co-amoxiclav than non-CF isolates and that azithromycin resistance in CF isolates was associated with current prescription of this macrolide. Further studies are required to determine when resistance develops, if it persists and if it impacts on the efficacy of antibiotic treatment of CF pulmonary infection. If treatment of Prevotella is indicated in CF, our findings suggest that antibiotics such as metronidazole, meropenem, piperacillin/tazobactam and chloramphenicol are likely to be most effective.
